Oxycodone in Combination With Parathoracic Nerve Block is Used for Postoperative Analgesia in Lung Cancer

Qianfoshan Hospital

Status and phase: Not yet enrolling; Phase 1

Conditions: Oxycodone

Treatments: Drug: Oxycodone 1mg/kg; Drug: Oxycodone 1.5mg/kg; Drug: Sufentanil

Study type: Interventional

Funder types: Other

Identifiers

NCT05742256

YXLL-KY-2022(116)

Details and patient eligibility

About

In this study, the effect of oxycodone combined with ultrasound-guided paravertebral nerve block on the postoperative analgesic effect of thoracoscopic lung cancer was investigated, and the effect and reasonable dose of oxycodone were explored, which provided a reference for the clinical multimodal analgesia after thoracoscopic lung cancer surgery.

Enrollment: 159 estimated patients

Sex: All

Ages: 60+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male or female, age > 60 years
2. Patients undergoing thoracoscopic lobectomy
3. ASA (American Academy of Anesthesiologists) Grades I-III
4. There were no obvious abnormalities in heart, liver, and kidney function
5. Sign the informed consent form for this clinical study

Exclusion criteria

1. History of oxycodone or sufentanil allergy
2. Renal or hepatic dysfunction
3. History of drug or alcohol abuse
4. Psychiatric disorders: schizophrenia, epilepsy, Parkinson's disease, myasthenia gravis
5. Those who have difficulty communicating due to coma, severe dementia, speech barrier, or those who cannot cooperate due to other diseases.
6. People with head trauma or other brain diseases -

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

159 participants in 3 patient groups

Test group 1(OCA group)

Experimental group

Treatment:

Drug: Oxycodone 1mg/kg

Test group 2(OCB group)

Experimental group

Treatment:

Drug: Oxycodone 1.5mg/kg

Control group(SF group)

Active Comparator group

Treatment:

Drug: Sufentanil